Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia

Zhiqian Tong\textsuperscript{a,1}, Jinling Zhang\textsuperscript{a,1}, Wenhong Luo\textsuperscript{b,1}, Weishan Wang\textsuperscript{c}, Fangxu Li\textsuperscript{a}, Hui Li\textsuperscript{b}, Hongjun Luo\textsuperscript{b}, Jing Lu\textsuperscript{a}, Jiangning Zhou\textsuperscript{e}, You Wan\textsuperscript{f}, Rongqiao He\textsuperscript{a,d,*}

\textsuperscript{a} State Key Lab of Brain and Cognitive Sciences, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
\textsuperscript{b} The Central Laboratory, Shantou University Medical College, Guangdong 515041, China
\textsuperscript{c} Beijing Hospital for the Elderly, Beijing, China
\textsuperscript{d} Lab of Mental Health, Institute of Psychology, Chinese Academy of Sciences, China
\textsuperscript{e} University of Science and Technology of China, Anhui, China
\textsuperscript{f} Neuroscience Research Institute, Peking University, Beijing, China

Received 4 March 2009; received in revised form 9 July 2009; accepted 26 July 2009

Abstract

It is widely known that exogenous formaldehyde exposure induces human cognitive impairment and animal memory loss; and recent studies show that formaldehyde at pathological levels induces A\textsubscript{β} deposition and misfolding of tau protein to form globular amyloid-like aggregates. Endogenous formaldehyde may be a marker for progressive senile dementia.

The aim of this study was to investigate the correlation of endogenous formaldehyde in urine of senile dementia and mini mental state examination (MMSE) scores.

Formaldehyde level was analyzed by high-performance liquid chromatography (with fluorescence detection) in human urine from dementia patients (\(n=141\)), patients with hypertension (\(n=33\)) or diabetes (\(n=16\)) and healthy individuals (\(n=38\)), autopsy hippocampus samples from Alzheimer’s disease (AD) patients and brains of three types of AD animal model: namely, senescence accelerated mice (SAMP8), APP-transgenic mice and APP/PS1-transgenic mice.

In a double-blind study, there was marked elevation of urine formaldehyde levels in patients (\(n=91\)) with dementia, and a slight increase in patients (\(n=50\)) with mild cognitive impairment. Urine formaldehyde level was inversely correlated with mini mental state examination scores (\(R\text{\textsubscript{s}}=-0.441, p<0.0001\)). Furthermore, formaldehyde levels were significantly increased in the autopsy hippocampus from Alzheimer’s patients (\(n=4\)). In SAMP8 brains the formaldehyde level was significantly increased, suggesting that the endogenous formaldehyde is related to aging in mice. The brain formaldehyde level in APP/PS1-transgenic (\(n=8\)) mice at age of 3 months and APP-transgenic (\(n=8\)) mice at age of 6 months was increased (0.56 ± 0.02 mM), respectively, as compared with their respective age-matched controls, when these two types of AD-like animals, respectively, started to form Aβ deposits and memory loss obviously. According to the level of formaldehyde in the brain of the transgenic mice, we treated normal mice with formaldehyde (0.5 mM, intraperitoneal administration) and observed the memory loss of the animal in Morris water maze trial.

Cognitive impairments for the senile dementia are probably related to endogenous formaldehyde levels; and the mini mental state examination scores referred to the evaluation of urine formaldehyde level in dementia patients may be used as a non-invasive method for the investigation and diagnosis of senile dementia.

© 2009 Published by Elsevier Inc.

Keywords: Formaldehyde; Urine; Mini mental state examination (MMSE) scores; Senile dementia; Alzheimer’s disease; One-carbon cycle

* Corresponding author at: State Key Lab of Brain and Cognitive Sciences, Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101, China. Tel.: +86 10 6488 9876; fax: +86 10 6485 3625.
E-mail address: herq@sun5.ibp.ac.cn (R. He).

\textsuperscript{1} These authors contributed equally to this work.

0197-4580/$ – see front matter © 2009 Published by Elsevier Inc.

Please cite this article in press as: Tong, Z., et al., Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol. Aging (2009), doi:10.1016/j.neurobiolaging.2009.07.013
1. Introduction

Senile dementia, for instance those related to Alzheimer’s disease (AD), is the most common form of dementia. The presence of amyloid-containing senile plaques together with neurofibrillary tangles has been shown in many investigations to be hallmarks of Alzheimer’s disease (Hardy and Selkoe, 2002). In clinical studies, neuropsychological tests such as the mini mental state examination (MMSE) are widely used to evaluate cognitive impairments for diagnosis. Although diagnostic sensitivity and specificity even in early disease stages are improved by cerebrospinal fluid (CSF) markers (Jellinger et al., 2008), more comprehensive test arrays are necessary to improve the reliability of results, particularly in the earliest stages of the disease (Pasquier, 1999; Tombaugh and McIntyre, 1992). Simple, non-invasive tests for early detection of degenerative dementia using biomarkers are urgently required (Corey-Bloom et al., 1995). However, at the present time, no extracerebral diagnostic markers such as urine, serum and connective tissue have been validated for the diagnosis of Alzheimer’s disease.

On one hand, it is known that exogenous formaldehyde is a ubiquitous compound with high cytotoxicity and genotoxicity. On the other hand, evidences show that endogenous formaldehyde is present in urine, blood and all cells including the brain. Endogenous formaldehyde content of rat brain approaches 0.1 mM/g wet weight as determined by mass spectrometry (Heck et al., 1982). Recent studies show that elevation of endogenous formaldehyde levels may be related to the pathogenic processes of neurodegenerative diseases (Kilburn et al., 1987; Perna et al., 2001). Formaldehyde at low concentrations results in amyloid-β deposition (Chen et al., 2006) and the structure of α-synuclein changes in vitro (Floor et al., 2006). Our previous study has also shown that excessive formaldehyde induces misfolding of tau protein and formation of globular amyloid-like aggregates that have high cytotoxicity in vitro and in vivo (Nie et al., 2007a,b). As described previously (Kilburn et al., 1987), exposure to formaldehyde leads to memory loss in rats and decreases in acetylcholine and norepinephrine levels, and also induces many forms of human impairment and changes in neurofilament proteins in hippocampal neurons (Perna et al., 2001). These changes show similarity to the pathological features of severe dementia.

Epidemiological investigations have shown that overexpression of semicarbazide-sensitive amine oxidase (SSAO), one of the enzymes in the pathway producing formaldehyde (Ferrer et al., 2002) and deficiency of aldehyde dehydrogenase class 2 (ALDH2), one of the enzymes that degrade formaldehyde (Kamino et al., 2000; Teng et al., 2001) are associated with an increased risk of late-onset Alzheimer’s disease. In clinical studies, an increase of endogenous formaldehyde in the blood and CSF has been found in multiple sclerosis (Khokhlov et al., 1989) which is often accompanied by gradual cognitive decline. Abuse of formaldehyde-laced marijuana induces a high occurrence of dysmnesia (Marceaux et al., 2008). These data suggest that elevated endogenous formaldehyde-induced brain lesions are involved in the pathogenesis of Alzheimer’s disease. As the urinary system is one of the main ways for endogenous formaldehyde to be excluded from the blood, we postulate that urine formaldehyde may be a non-invasive biomarker for diagnosing dementia. In this work, we sought to determine whether formaldehyde levels in the urine and brain tissues were associated with the degree of senile dementia.

2. Patients and methods

2.1. Participants

Patients (n = 141) with varying degrees of dementia underwent a standardized clinical assessment, which included a medical history, and physical and neurological examination together with mini mental state examination (MMSE) laboratory tests, psychometric evaluation, electroencephalograph (EEG) and brain magnetic resonance imaging (MRI). All patients met NINCDS-ADRDA criteria for probable dementia on clinical grounds. The degree of dementia was scored as mild cognitive impairment (MCI), medium and severe as previously described (McKhann, 1984). Thirty-eight healthy controls and 49 patients with common aging-related diseases (hypertension or diabetes) were also evaluated. Informed consent was obtained for all participants, and for patients with dementia, informed consent was obtained from relatives. This clinical investigation was approved by the Ethics Committee for Beijing Hospital for the Elderly, China.

2.2. Brain tissues collection

Autopsy hippocampus tissues from 4 healthy controls and 4 AD patients were provided by the Netherlands Brain Bank (NBB). The age-related and AD-like animal models, senescence accelerated mice, SAMP8 and SAMP1, were provided by Beijing University (China). APP-transgenic mice and APP/PS1-transgenic mice were provided by the Chinese Academy of Medical Sciences (Beijing). All animal experimental procedures described below were approved by the Ethics Committee for the Chinese Academy of Sciences.

2.3. Urine samples collection

Patients with renal disease and urine abnormalities were excluded from the study. Morning urine samples of patients with MCI, medium and severe dementias were taken before breakfast. Urine samples from healthy controls with neither any neurological disorders nor known alcohol and drug abuse, were also taken (Ghanbari et al., 1998).

2.4. Formaldehyde level detected by Flu-HPLC

Ten milliliters of urine was collected from each participant and immediately placed on ice and stored at −70 °C. To
avoid the samples being thawed too many times, the urine
was freshly analyzed or divided into equal parts to be stored
for only one time use. After centrifugation (3000 rpm, 4 °C,
10 min), supernatant fractions of urine samples and brain
homogenates (weight of brain tissue:ultrapure water = 1:4)
were analyzed by high-performance liquid chromatography
with fluorescence detection (Fluo-HPLC) as described (Luo
et al., 2001). Briefly, an aliquot of 0.2 ml human urine or
brain homogenate was pipetted into a 2-ml glass vial, to
which 0.8 ml water, 0.1 ml ampicillin solution (2.5 mg/ml,
in water) and 0.25 ml TCA (20%, w/v, in water) were added.
The vial was capped (air tight) and vortexed vigorously for
30 s and then heated in a 90 °C water bath for 1 h. After
cooling to room temperature, the contents of the vial were
transferred to a 10-ml glass centrifuge tube. The vial was
rinsed twice with 1 ml diethyl ether which was also trans-
ferrred to the centrifuge tube. After addition of a small amount
of sodium chloride (about 0.5 g) the centrifuge tube was vor-
texed vigorously for 1 min. After centrifugation (1000 × g)
for 5 min, the upper layer (organic phase) was transferred to
a 5-ml test tube. The aqueous phase in the centrifuge tube
was extracted with another 2 ml diethyl ether and the ether
extracts were combined. The diethyl ether was evaporated to
dryness under a gentle stream of nitrogen. The residue was
redissolved in 0.5 ml acetonitrile–water (50:50), ready for LC
analysis. 0.2 ml water was used as a reagent blank instead of
the 0.2-ml sample, and the same procedure was followed.

The formaldehyde derivative eluted from the HPLC col-
umn at a retention time of 8 min. Methanol, formic acid,
acetaldehyde and other aldehyde compounds did not inter-
fere with the analysis of formaldehyde. In fact, no specific
chromatographic peak was detected when acetaldehyde was
reacted with ampicillin under the same reaction conditions.
The formaldehyde standard curve was made with analytic
purified formaldehyde (see Fig. 1A). The peak area count
(mV) of the fluorescent formaldehyde derivative was used to
determine urine formaldehyde from patients with different
degrees of dementia, healthy controls, and blanks (water).
Laboratory analyses and clinical investigations were carried
out in a double-blind manner.

To testify the reaction of resveratrol with formaldehyde,
the two compounds (1 mM) were incubated in PBS for
40 min. Then, the solution was analyzed by Fluo-HPLC.

2.5. Behavioral assessment of cognitive functions by
Morris water maze test

Spatial learning memory was assessed by the Morris
water maze behavioral test, as described previously (Morris,
1984). Mice of four groups were intraperitoneally admin-
istrated with physiologic saline, formaldehyde (0.5 mM),
formaldehyde with resveratrol (0.5 mM), and resveratrol

Fig. 1. Chromatogram of human urine samples using Fluo-HPLC. (A) The formaldehyde standard curve. (B) Typical peaks of the blank control—water. (C)
Peaks of urine of healthy controls. (D) Peaks of patients with low-grade dementia. (E) Peaks of medium dementia. (F) Peaks of severe dementia.
Severe degrees of dementia exceed 42% (21/50), 82.05% patients with mild cognitive impairment (MCI), medium and (hyde level was not markedly correlated with age of patients < 0.001). Meantime, we also found that urine formaldehyde related with MMSE scores of the patients (with the degree of dementia (see Fig. 1). Table 1 shows hyde derivative reacted with ampicillin exhibits positively shown in Fig. 1. The fluorescent peak area of the formaldehyde in senile dementia and the level of urine formaldehyde, of senile dementia was 38.89% for diabetic patients and 33.33% for patients had cognitive disorders (dementia). The incidence of dementia was 38.89% for diabetic patients and 33.33% for those with hypertension, showing a much higher incidence than that (2.5–5%) of the 60–65 year old age bracket in an epidemiological survey of Alzheimer’s disease in Chinese subjects (Yang, 2008). Urine formaldehyde in these patients was also significantly higher (p < 0.01) than that of healthy individuals. However, we did not detect an elevated level of urine formaldehyde in the patients with only hypertension or diabetes, i.e. no significant differences in urine formaldehyde levels were observed between healthy controls and patients with hypertension (or diabetes) whose MMSE scores were normal (see Fig. 2D). But, the levels of the diabetes (or hypertension) patients with and without dementia are significantly different from those of the control participants (see Fig. 2C).

3.2. Urine formaldehyde levels of dementia patients with age-related diseases

A recent epidemiological survey has shown that hypertension and diabetes play roles as vascular risk factors for senile dementia (Martinez et al., 2008). Thus, here we paid attention to patients with these disorders. Our investigation included 54 patients with diabetes and 24 ones with hypertension (see Fig. 2C). Among them, 21 diabetes and 8 hypertension patients had cognitive disorders (dementia). The incidence of dementia was 38.89% for diabetic patients and 33.33% for those with hypertension, showing a much higher incidence than that (2.5–5%) of the 60–65 year old age bracket in an epidemiological survey of Alzheimer’s disease in Chinese subjects (Yang, 2008). Urine formaldehyde in these patients was also significantly higher (p < 0.01) than that of healthy individuals. However, we did not detect an elevated level of urine formaldehyde in the patients with only hypertension or diabetes, i.e. no significant differences in urine formaldehyde levels were observed between healthy controls and patients with hypertension (or diabetes) whose MMSE scores were normal (see Fig. 2D). But, the levels of the diabetes (or hypertension) patients with and without dementia are significantly different from those of the control participants (see Fig. 2C).

3.3. Brain formaldehyde was increased in AD patients and AD animal models

To clarify the relationship between endogenous formaldehyde and dementia, we measured the formaldehyde in human...
and animal brains. As depicted in Fig. 3A, formaldehyde level from homogenates of autopsy hippocampus of AD patients (n = 4) showed a marked elevation (p < 0.05) as compared with those of healthy controls (n = 4).

Aging is the most important risk factor for senile dementia, and thus we investigated the correlation of endogenous formaldehyde with aging. Senescence accelerated SAMP8 mice which have deficiency in learning and memory and SAMP1 mice which have no distinct cognitive disorders were employed to test the endogenous formaldehyde levels in brain (see Fig. 3B). The formaldehyde level in brain homogenates from 5- and 10-month-old SAMP8 mice was higher than that for SAMP1 counterparts. This indicates that the concentration of cerebral endogenous formaldehyde is related to aging in SAMP mice.

Furthermore, to investigate whether endogenous formaldehyde levels are related to dementia, APP/PS1 transgenic mice were employed as an AD model because of their more robust amyloid-β (Aβ) deposition and dementia (Trinchese et al., 2004). The brain formaldehyde of APP/PS1 transgenic mice was significantly higher (p < 0.01) at 3 months than that of their respective age-matched controls (see Fig. 3C). It is known that this transgenic mouse starts to deposit Aβ in the brain at the age of 2 months and shows abnormal long-term potentiation (LTP) as early as the age of 3 months. It appears that the increase of brain formaldehyde accompanies the initiation of Aβ deposits and the onset of abnormal memory in these transgenic mice.

To confirm that the endogenous formaldehyde level of AD-like transgenic mice was higher than the control during the initiation of Aβ deposits, APP-transgenic mice were used. As Aβ deposits in the brain of these transgenic mice begin at 6–7 months (Kawarabayashi et al., 2001), we measured the formaldehyde level in the brain at 6 and 12 months. As shown in Fig. 3D, brain formaldehyde was significantly increased at 6 months, and became similar to that of the controls at 12 months. This suggests again that the onset of Aβ deposits is accompanied with an increase in brain formaldehyde.

Please cite this article in press as: Tong, Z., et al., Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol. Aging (2009), doi:10.1016/j.neurobiolaging.2009.07.013
3.4. Formaldehyde-induced impairments of mice in spatial reference memory function

According to the level of formaldehyde in the brain of the transgenic mice as mentioned above, 0.5 mM formaldehyde was intraperitoneally administered to normal adult mice during learning trials in a Morris water maze test. We found that spatial reference memory function was significantly impaired after treated with formaldehyde for 30 days. Resveratrol, a natural formaldehyde scavenger (see Fig. 4C), obviously attenuated this damage, as reflected by reduced escape latency time as well as progressive learning trials (see Fig. 4A and B). The resveratrol could functionally remove formaldehyde in mice, as the formaldehyde level in brains of mice treated with resveratrol (0.5 mM) was significantly decreased (see Fig. 4D). Formaldehyde levels in brains of rats were inversely correlated to behavioral performance that time of staying in the target quadrant of the hidden platform (see Fig. 4E). This suggests that excessive endogenous formaldehyde induces cognitive impairment.

4. Discussion

Formaldehyde is produced constitutively in the human body, and is present intracellularly and extracellularly in nuclei (Shi et al., 2004), cytoplasm (Lyles, 1996), blood (Andres et al., 2001) and CSF (Khokhlov et al., 1989). Several enzymes in the liver such as ALDH2, ADH1 and catalase can catalyze the reaction that oxidizes formaldehyde to formic acid (Teng et al., 2001). Catalysis of the conversion of formaldehyde to formate via glutathione-dependent formaldehyde dehydrogenase (FDH; also known as class III alcohol dehydrogenase, ADH3), takes place in all tissues of the human body as a consequence of the regulation of endogenous formaldehyde (Heck et al., 1982). By this pathway, endogenous or exogenous formaldehyde is eliminated from the body as metabolites, primarily as formate or CO2. Endogenous formaldehyde accumulates in cells when FDH activity decreases. Excess levels of formaldehyde can be involved in cross-linkages between proteins and DNA or can enter the “one-carbon intermediary metabolic pool”.

Please cite this article in press as: Tong, Z., et al., Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol. Aging (2009), doi:10.1016/j.neurobiolaging.2009.07.013
Formaldehyde is able to penetrate the blood–brain barrier (Shcherbakova et al., 1986), is transported in circulation and is eliminated from the body through urine and breath in addition to enzymic catalytic pathways (Estonius et al., 1996). Formaldehyde is much more rapidly dialyzed by the kidneys and excreted through the urinary bladder than by respiration (Spanel et al., 1999). Laboratory tests can directly measure endogenous formaldehyde in urine, blood, and breath.

As an active organic molecule, formaldehyde reacts rapidly with protein α-/ε-amino groups. However, although serum proteins react rapidly with formaldehyde, there are few proteins in urine to react with formaldehyde. Thus mea-
measurement of urine formaldehyde by reacting with ampicillin (fluorescent reagent) is much less affected than that of serum formaldehyde. Urine is also much more convenient to sample and store than blood, CSF or brain tissue. Thus this study may provide a simple way for the diagnosis of senile dementia patients by using urine formaldehyde as a clinical criterion.

To guarantee the reproducibility of analytical results, aliquots of the first urine in the morning were taken before patients had breakfast. Dementia patients with renal disease and normal controls who had consumed alcohol within the previous week, or taken medicine within the previous two weeks were excluded. During trials, all subjects had a normal diet, except for any consumption of fatty and spicy foods. Patients with the peripheral bladder or prostate cancer were excluded because their urine formaldehyde was found to increase (2–8 folds higher than normal) as reported previously (Spanel et al., 1999). Proliferating cancer cells are known to secrete more formaldehyde (Tong et al., 2008). This is to say, tumor-derived formaldehyde is accumulated to a high level in urine, but it is not resulted from damage of kidney function. However, it is relatively easy to distinguish patients with these types of cancer by standard clinical diagnostic procedures. According to the reports of other authors who investigate dementia patients in clinical trials (Tombaugh and McIntyre, 1992), we used the mini mental state examination (MMSE) as an entry criterion for different degrees of aging dementia.

We found that MMSE scores were significantly correlated with urine formaldehyde ($R_s = −0.441, p < 0.001$), and urine formaldehyde levels of patients with medium and severe degrees of dementia were 3-fold higher than those of the controls. Furthermore, the urine formaldehyde concentrations of dementia patients were positively correlated with the degree of dementia (percentages of patients with elevated formaldehyde levels were 42% (21/50), 82.05% (32/39) and 88.46% (46/52), for MCI, medium and severe dementia patients, respectively). This suggests that urine formaldehyde concentration can be used as a criterion to support MMSE scores in the diagnosis of patients with medium and severe dementia.

For MCI patients, however, urine formaldehyde concentrations were not altered as significantly as those for medium and severe dementia patients. The urine formaldehyde level for senile dementia patients with MCI was slightly elevated ($p = 0.098$) compared to that of healthy controls. However, in 42% (21/50) of patients, urine formaldehyde level exceeded the average level of healthy controls. Thus, endogenous formaldehyde level may also be useful for identifying incipient dementia.

At present, there are no clinical chemical methods for identifying MCI. Urine formaldehyde level is related to MMSE scores of MCI-like aging patients to a certain extent. This provides a chance for sensitive formaldehyde assay. In fact, 42% of MCI patients had significantly increased levels of urine formaldehyde. Patients with MCI at risk of developing dementia are usually lowed clinically for 4–6 years, and the urine formaldehyde in the remaining 58% (29/50) of MCI-like patients in our study should be further consecutively investigated.

Urine formaldehyde concentration was markedly elevated in patients with different types of medium and severe dementia, for example 41 patients with vascular dementia, 22 with senile dementia, 12 with mixed dementia and 16 patients with other types of dementia all showed elevated levels of urine formaldehyde. Thus, urine formaldehyde and MMSE scores cannot be used on their own to distinguish between different types of dementia. Elevation of urine formaldehyde could be used to screen for cognitive impairments but does not help us to distinguish between vascular and senile dementia. However, the mechanism underlying the relationship between urine formaldehyde and cognitive impairment remains to be further investigated.

To support our clinical investigation data, we analyzed the formaldehyde content of the autopsy hippocampus from AD patients (Alzheimer’s disease is a disease that results from brain lesion (Hardy and Selkoe, 2002)). As indicated in the results section, the concentration of endogenous formaldehyde was increased in the autopsy hippocampus relative to controls. A natural formaldehyde capturer (Szendele et al., 1998), resveratrol, provides effective defense against cancer and neurodegenerative disease including Alzheimer’s disease (Rocha-González et al., 2008; Saiko et al., 2008). Recent research has also shown that dietary supplementation with resveratrol reduces senile plaque (SP) pathology in a APP/PS1-transgenic model of Alzheimer’s disease (Karuppagounder et al., 2008). This supports the hypothesis that excessive endogenous formaldehyde is involved in the pathogenesis of these diseases.

To provide indirect support that endogenous formaldehyde has potential for use as a clinical criterion, we first employed SAMP1 and SAMP8 mice (Banks et al., 2007) to test whether endogenous formaldehyde levels are related to aging. As reported previously, SAMP8 mice at 2–5 months old develop memory impairment which is associated with level of acetylcholine and activity of choline acetyltransferase (ChAT) decreases in the hippocampus (Kuo et al., 1996; Onozuka et al., 2002). Elevation of formaldehyde levels in the brain by formaldehyde injection also leads to memory loss with levels of neurotransmitters such as acetylcholine and norepinephrine decreases in rats (Kilburn et al., 1987; Perna et al., 2001). In our results, significant elevation of endogenous formaldehyde in the brain occurred simultaneously with the onset of cognitive impairment in this senile dementia animal model. Although over-expression of APP gene has been found in brain, there are no typical senile plaques in the hippocampus and cortex in this senescence accelerated animal model (Banks et al., 2007). This hints that excessive formaldehyde directly induces cognitive impairments.

In transgenic AD animal model, increases in brain formaldehyde and the development of abnormal LTP levels concurred (from as early as 3 months of age) to in APP/PS1-transgenic mice (Trinchese et al., 2004). Interest-
ingly, reduced LTP parallels plaque appearance, increased Aβ levels and abnormal short-term memory (working memory). In APP-transgenic mice, brain formaldehyde also increased at the early stage (6 months old) during which Aβ starts to deposit in the brain. Moreover, in both APP/PS1- (6 months old) and APP- (12 months old) transgenic mice, brain formaldehyde levels were not significantly different from those of their respective age-matched controls (see Fig. 3C and D), but more and more typical senile plaques were detected in the brain of these two transgenic types of AD mice (Trinchese et al., 2004; Karuppagounder et al., 2008). Previous studies have shown that excessive formaldehyde reacts with Aβ1–42 to form amyloid-β deposition (Chen et al., 2006), and formaldehyde at pathological level induces misfolding of tau protein to the formation of globular amyloid-like aggregates (Nie et al., 2007a,b). This suggests that excessive endogenous formaldehyde may play a role in the initiation of Aβ deposition in these transgenic mice.

Unexpectedly, although immunization with Aβ1–42 results in clearance of amyloid plaques in APP-transgenic mouse and patients with Alzheimer’s disease, this clearance has not prevented progressive neurodegeneration. Thus, reducing total Aβ may be of limited therapeutic benefit to recovery of cognitive decline in a higher mammalian model of human brain aging and disease (Head et al., 2008; Holmes et al., 2008). We speculate that although Aβ1–42 plays a critical role in formation of senile plaques of AD; abnormal excessive formaldehyde not only results in Aβ deposition but also may directly induce cognitive impairments. Therefore, the role of endogenous formaldehyde in pathogenesis of Alzheimer’s disease should be further investigated. These data also hint that these AD-like animal models partially simulate pathological characters of Alzheimer’s disease in human beings.

To explore direct evidence that formaldehyde induces memory loss, normal adult mice were treated by formaldehyde (0.5 mM) for 30 days. Spatial reference memory function impairments of adult mice were significantly observed during learning trials in a Morris water maze test (see Fig. 4A and B). Previous research also indicates that memory behavioral changes in rats are due to chronic oral and systemic formaldehyde (60 days) (Bhatt and Panchal, 1992). Furthermore, other evidence shows that formaldehyde (i.p. 10 days) induces oxidative frontal cortex and hippocampal tissue damage of rats (Gurel et al., 2005). Formaldehyde is a small molecule which is capable of penetrating the blood–brain barrier (Schcherbakova et al., 1986). Exposure to exogenous gaseous formaldehyde leads to its accumulation in brain of rats (Cui, 1996). In our study, both elevated formaldehyde level in the brain and memory loss were found after formaldehyde treatment (i.p.). Resveratrol, a natural formaldehyde scavenger (Szende et al., 1998), obviously attenuated the formaldehyde-induced damage of learning and memory by decreasing formaldehyde level in vitro and in vivo (see Fig. 4C–E). Deficiency of aldehyde dehydrogenase class 2 (ALDH2), one of the enzymes that degrade formaldehyde, has been found to be associated with an increased risk of late-onset Alzheimer’s disease, and leads to memory loss (Kamino et al., 2000; Teng et al., 2001). These data further indicate that excessive endogenous formaldehyde directly induces cognitive impairment. Although Aβ1–42 plays a critical role in formation of senile plaques of AD, abnormal formaldehyde not only results in Aβ deposition but also directly induces memory loss. Therefore, endogenous formaldehyde probably participates in the pathogenesis of Alzheimer’s disease.

As described previously (Tong et al., 2008), several mechanisms may lead to the elevation of formaldehyde levels in vivo, inducing a chronic imbalance between the production and degradation of endogenous formaldehyde with age (see Fig. 3). First, as hypothesized by Barker and coworkers (Barker et al., 1980), the excessive formaldehyde resulted from the disorder of “one-carbon units”, leads to a genetically determined brain lesion. Deficiency of folate, B12, or 5,10-methylene THF-reductase (Reynolds, 2006; Stumpp, 1997), which is correlated with the risk of stroke and dementia, leads to formaldehyde accumulation (Kalász, 2003) via the “one-carbon-cycle”. For example, injection (i.c.v.) of S-adenosylmethionine (SAM) induces an increase in formaldehyde to neurotoxic levels in the brain (Barker et al., 1980; Lee et al., 2008). Second, endogenous formaldehyde is produced by microsomal cytochrome P-450 and is dependent upon oxidation of xenobiotics, including various drugs and environmental pollutants such as neurotoxic compounds: formaldehyde, paraquat, and mercury (Retalvi et al., 1998). N-demethylation, O-demethylation and S-demethylation result in the production of formaldehyde (Taranenko and Efimova, 2007). Third, over-expression or deficiency of genes involved in formaldehyde metabolism such as SSAO (Ferr er et al., 2002) and ALDH2 (Kamino et al., 2000; Teng et al., 2001), also induces formaldehyde accumulation. In addition, formaldehyde is also generated by lysine-specific demethylase 1 (LSD1), lipid peroxidation (LPO) and stress (Yu et al., 1997; Kang et al., 2007). These environmental and genetic factors related with formaldehyde metabolism may affect AD pathogenesis.

As described above, excessive endogenous formaldehyde leads to cognitive impairment. Urine formaldehyde level is positively correlated to the degree of aging dementia. Evaluation of endogenous formaldehyde in the urine has potential for use as a non-invasive and convenient method for the investigation and diagnosis of dementia. Our work also raises the possibility that urine formaldehyde could be used as a marker for the assessment of therapeutics.

Disclosure statement

The authors declare that they have no competing interests to disclose.

Uncited reference

Butcher (2007).
Acknowledgments

The authors thank Xueqin Wu, Jin Chen, Chuiyan Zhang and Jianwen Chen for collecting human urine samples. The authors are also grateful to Xu Yang for their advice on editing and useful ideas in the discussion.

This study was supported by grants from the Natural Scientific Foundation of China NSFC30621004, CAS-KSCX2-YW-R-119 and 973-Project (2006CB911003).

Appendix A. Supplementary data


References


Q4

Changes in the septohippocampal cholinergic system following removal of molar teeth in the aged SAMP8 mouse. 133, 197–204.


